MedPath

The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis

Not Applicable
Completed
Conditions
Gastroesophageal Reflux Disease
Esophagitis
Reflux Esophagitis
Registration Number
NCT01733810
Lead Sponsor
Dallas VA Medical Center
Brief Summary

The purpose of this study is to determine the role of hypoxia inducible factor (HIF)-2a on the production of inflammatory cytokines that lead to reflux esophagitis.

Detailed Description

Reflux esophagitis is thought to be caused by gastric acid that refluxes into the esophagus, causing injury. Newer data suggest that reflux of gastric juice into the esophagus stimulates HIF-2a, which increases production of inflammatory cytokines. These cytokines are thought to lead to reflux esophagitis. The investigators plan to study the relationship of HIF-2a to inflammatory cytokines in patients with known gastroesophageal reflux disease and reflux esophagitis.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
12
Inclusion Criteria
  • U.S Veteran
  • History of Los Angeles Grade C erosive esophagitis
Exclusion Criteria
  • Inability to provide informed consent
  • Esophageal varices
  • Warfarin use
  • Coagulopathy that precludes safe biopsy of the esophagus
  • Comorbidity that precludes safe participation in the study
  • Allergy to fluorescein sodium
  • Pregnancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
change in esophageal inflammation from baseline to 14 daysday 0 and day 14

inflammation of the squamous esophageal mucosa will be measured at baseline and at 14 days

Secondary Outcome Measures
NameTimeMethod
change in HIF-2a levels from baseline to 14 daysday 0 and day 14

Amount of HIF-2a present will be measured at baseline and at 14 days

Trial Locations

Locations (1)

Dallas VA Medical Center

🇺🇸

Dallas, Texas, United States

Dallas VA Medical Center
🇺🇸Dallas, Texas, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.